AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Innovative Tech Boosts Control Bionics' Growth Prospects
October 10, 2024 07:50 PM AEDT| By Team Kalkine MediaHighlights:,Control Bionics targets 20% revenue growth and near-term EBITDA positivity.,Sigma Healthcare led healthcare sector gains with a 186% rise over the year.,Noxopharm secures manufacturing for its autoimmune diseases trial.,Control Bionics (A...
Imagion Biosystems Raises $3 Million for Cancer Diagnostics Advancements
October 10, 2024 07:00 PM AEDT| By Team Kalkine MediaHighlights,Imagion Biosystems secures $3 million through a capital raise.,Funds to advance the MagSense platform, targeting cancer diagnosis improvements.,Positive results from Phase 1 breast cancer study for MagSense technology.,Imagion Biosystems (...
Recce Pharmaceuticals Advances Testing of Skin Infection Gel
October 09, 2024 06:06 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals progresses its Phase II trial for a topical gel.,Early data shows the gel is safe and demonstrates positive antibacterial effects.,Recruitment for the trial is on track to finish by the end of the year.,Recce Pharmace...
Orthocell Gains Regulatory Approval for Nerve Repair Product in Singapore
October 08, 2024 03:38 PM AEDT| By Team Kalkine MediaHighlights,Orthocell receives Singapore regulatory approval for Remplir.,Expansion plans include ASEAN markets and upcoming US FDA approval.,Record quarterly revenue of $2.03 million reported.,West Australian-based regenerative medicine company Ortho...
Orthocell Secures Singapore Regulatory Approval for Nerve Repair Product, Remplir™
October 08, 2024 01:40 PM AEDT| By Team Kalkine MediaKey Points:,Orthocell has secured regulatory approval in Singapore for its nerve repair product, Remplir, marking the first major international clearance outside of Australia and New Zealand.,The company is in advanced discussions with an internation...
Audeara Secures Major $570,000 Purchase Order from Clinico, Shares Surge 10.4%
October 08, 2024 01:23 PM AEDT| By Team Kalkine MediaKey Points:,Clinico, Taiwan’s largest hearing aid retailer, has placed a $570,000 purchase order with Audeara for healthy hearing earbuds.,The earbuds will be marketed and distributed across Taiwan and China, with an official launch expected in Q2 FY...
Orthocell Secures Key Approval in Singapore for Nerve Repair Product Remplir™
October 08, 2024 12:17 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,receives regulatory approval in Singapore for its,Remplir,™ product.,Singapore acts as a gateway to other ASEAN markets for,Orthocell,.,Remplir,™ targets a global market opportunity exceeding US,$3.5 billion,.,Orthocell Ltd (ASX:...
Lumos Diagnostics Raises A$10 Million for Growth and Expansion
October 08, 2024 11:11 AM AEDT| By Team Kalkine MediaHighlights,Lumos Diagnostics completed a successful fundraising round.,The company raised a total of A$10 million through an entitlement offer.,Funds will be used for growth initiatives, including a key U.S. regulatory milestone.,Lumos Diagnostics Ho...
Pro Medicus (ASX:PME) Secures AU$98M, 8-Year Contract Renewal with Mercy Health
October 07, 2024 04:27 PM AEDT| By Team Kalkine MediaKey Points:,Pro Medicus' U.S. subsidiary signs an eight-year contract renewal with Mercy Health, valued at A$98 million.,The deal includes Visage 7 Viewer and Visage 7 Open Archive, with a higher per-transaction fee compared to the original contract....
Orthocell (ASX:OCC) Records Strong Growth in 2024
October 07, 2024 03:10 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,achieved record revenue of A$2.03 million in Q3 2024.,Demand for key products Striate+ and,Remplir,continues to drive growth.,US FDA approval for,Remplir,could unlock a,$1.6 billion,nerve repair market.,Orthocell Ltd (ASX:OCC), a...
Mesoblast (ASX:MSB) Poised for Breakthrough as FDA Decision Nears
October 07, 2024 01:32 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast shares have risen by 65% in the past month.,FDA approval for its stem-cell therapy,Ryoncil,is expected soon.,Mesoblast is advancing six programs in phase III clinical trials.,Mesoblast Limited (ASX:MSB), a leader in stem-cell the...
Cochlear Limited (ASX:COH) Sees Revised Valuation Amid Market Shifts
October 07, 2024 01:25 PM AEDT| By Team Kalkine MediaHighlights:,Cochlear's,stock declined over 13% after the August results, leading to a,reevaluation,.,Citi analysts have revised the price target for Cochlear from $255 to $305, citing a valuation,adjustment.,**,Cochlear's,price-earnings ratio for fis...
Chimeric Therapeutics (ASX:CHM) Reports Cancer Treatment Breakthrough
October 07, 2024 12:58 PM AEDT| By Team Kalkine MediaHighlights,Chimeric Therapeutics reports a complete response in a,leukaemia,patient during its latest drug trial.,The combination of ‘CORE-NK’ and,Vactosertib,shows potential in treating advanced cancer.,The ongoing trial aims to,enrol,12 patients, w...
Neuren Pharmaceuticals (ASX:NEU) Advances FDA-Approved Phase 3 Trial
October 07, 2024 12:39 PM AEDT| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals received positive FDA feedback for its Phase 3 trial.,The trial will focus on children with Phelan-McDermid Syndrome (PMS), testing NNZ-2591.,Neuren,is preparing trial sites and service providers for the next phase.,...
Nyrada (ASX:NYR) Advances NYR-BI03 Drug with Successful Safety Study
October 07, 2024 12:05 PM AEDT| By Team Kalkine MediaHighlights,Nyrada,completed a safety study for its NYR-BI03 drug candidate.,The drug is being developed to treat stroke and traumatic brain injury (TBI).,Phase 1 human trials are expected to begin by late 2024.,Sydney-based Nyrada Inc (ASX:NYR) has t...
Immuron (ASX:IMC) Advances Research on Enteric Disease Treatment
October 07, 2024 11:17 AM AEDT| By Team Kalkine MediaHighlights,Immuron,(,ASX:IMC,) supports US military research on a new treatment for enteric diseases.,Interim trial results show limited protective efficacy against Campylobacter.,The trial does not affect,Immuron's,plans for,Travelan,® or its FDA me...
A Closer Look at Insider Transactions at Aroa Biosurgery (ASX:ARX)
October 07, 2024 10:58 AM AEDT| By Team Kalkine MediaHighlights,Insider directors of Aroa Biosurgery have recently increased their stakes in the company.,Insider purchases have been made at prices higher than the current market rate, reflecting confidence in the stock.,Insider ownership stands at 25%,...
Control Bionics (ASX:CBL) Reports Rising NDIS Approvals and New Leasing Programs
October 04, 2024 06:04 PM AEST| By Team Kalkine MediaHighlights,Control Bionics sees rising NDIS approvals after delays.,New leasing programs launched for communication devices in Australia.,Rights issue underway to support product commercialization and expansion.,After experiencing industry-wide delay...
Cochlear (ASX:COH) Shares Rebound After Citi Upgrade, Forecasts Stronger Growth
October 04, 2024 03:29 PM AEST| By Team Kalkine MediaKey Points:,Cochlear's stock rose 1.5% to AU$291.92 after Citi upgraded the stock from "sell" to "neutral.",Citi raised its price target to AU$305, citing expected revenue and profit growth, particularly in the Adults/Seniors market.,Cochlear's FY24...
Lumos Diagnostics Secures Funding for FebriDx® Diagnostic Tool Expansion
October 04, 2024 12:42 PM AEST| By Team Kalkine MediaHighlights:,Funding Achievement,:,Lumos Diagnostics Holdings Ltd (ASX: LDX, OTC: LDXHF) has secured approximately,US$2,984,571,from BARDA to advance its,FebriDx,® diagnostic tool.,Rapid Diagnostic Capabilities,:,FebriDx,®,utilizes,a fingerstick blood...
Advertise your brand on Kalkine Media